Novo Nordisk A/S : Insulin degludec passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan (31 August 2012)

Read the full announcement in PDF format

Novo Nordisk today announced that insulin degludec has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process will now be an official approval from the Ministry of Health, Labour and Welfare (MHLW).

The First Committee on Drugs of Pharmaceutical Affairs serves as an advisory body to the MHLW, related to pharmaceuticals including new drug applications. The passing of the review by the drug committee is a critical milestone in the Japanese review process prior to a marketing authorisation from the MHLW.

"We are very excited about the result of the review of insulin degludec," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "This is a significant milestone towards what may be the first approval of insulin degludec, an insulin with potential to fulfil unmet medical needs for millions of people with diabetes who require insulin."

Novo Nordisk expects to receive marketing authorisation from the MHLW within a few months and that insulin degludec will be launched shortly after completion of the subsequent price negotiations.

About insulin degludec

Insulin degludec is a once-daily, ultra-long-acting basal insulin analogue discovered and developed by Novo Nordisk. Insulin degludec has a distinct slow absorption which provides a flat and stable action profile. Insulin degludec has been studied in a large-scale clinical trial programme, BEGIN(TM), examining its impact on glucose control, hypoglycaemia and the possibility to flexibly adjust insulin degludec dosing time to suit patient needs.

Insulin degludec was submitted for regulatory approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) in December 2011 and to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in September 2011. In addition, applications have been submitted for regulatory approval in Canada, Switzerland and a range of other countries.

Mike Rulis Kasper Roseeuw Poulsen
Tel: (+45) 3079 3573 Tel: (+45) 4442 4303
Frank Daniel Mersebach
Tel: (+45) 4442 0604
Lars Borup Jacobsen
Tel: (+45) 3075 3479
In North America:
Ken Inchausti Jannick Lindegaard
Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575

Company Announcement No 54 / 2012




Search for Danish versions and earlier news releases:

Search for:


Sign up for the latest news from Novo Nordisk




RSS feeds

Click here to go to the download centre to download presenations, reports or magazines